GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medeon Biodesign Inc (ROCO:6499) » Definitions » Gross Profit

Medeon Biodesign (ROCO:6499) Gross Profit : NT$8.4 Mil (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Medeon Biodesign Gross Profit?

Medeon Biodesign's gross profit for the three months ended in Mar. 2024 was NT$4.2 Mil. Medeon Biodesign's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was NT$8.4 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Medeon Biodesign's gross profit for the three months ended in Mar. 2024 was NT$4.2 Mil. Medeon Biodesign's Revenue for the three months ended in Mar. 2024 was NT$47.1 Mil. Therefore, Medeon Biodesign's Gross Margin % for the quarter that ended in Mar. 2024 was 8.81%.

Medeon Biodesign had a gross margin of 8.81% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

During the past 12 years, the highest Gross Margin % of Medeon Biodesign was 71.43%. The lowest was 5.83%. And the median was 41.04%.


Medeon Biodesign Gross Profit Historical Data

The historical data trend for Medeon Biodesign's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medeon Biodesign Gross Profit Chart

Medeon Biodesign Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 481.12 186.24 46.30 28.63 186.81

Medeon Biodesign Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.38 6.37 4.24 0.04 4.15

Competitive Comparison of Medeon Biodesign's Gross Profit

For the Medical Instruments & Supplies subindustry, Medeon Biodesign's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medeon Biodesign's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medeon Biodesign's Gross Profit distribution charts can be found below:

* The bar in red indicates where Medeon Biodesign's Gross Profit falls into.



Medeon Biodesign Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Medeon Biodesign's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as

Gross Profit (A: Dec. 2022 )=Revenue - Cost of Goods Sold
=298.317 - 111.505
=186.8

Medeon Biodesign's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=47.141 - 42.987
=4.2

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$8.4 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Medeon Biodesign's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=4.2 / 47.141
=8.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Medeon Biodesign  (ROCO:6499) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Medeon Biodesign had a gross margin of 8.81% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Medeon Biodesign Gross Profit Related Terms

Thank you for viewing the detailed overview of Medeon Biodesign's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Medeon Biodesign (ROCO:6499) Business Description

Traded in Other Exchanges
N/A
Address
No. 116, HouGang Street, 7th Floor, Shilin District, Taipei, TWN, 11170
Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.

Medeon Biodesign (ROCO:6499) Headlines

No Headlines